Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.California-based biopharmaceutical firm VaxGen has entered into an amended lease agreement to secure building space to support the production of its recombinant anthrax vaccine, rpa102.
Subscribe to our email newsletter
The new lease replaces VaxGen’s previous sublease for approximately 50,000 square feet and provides an additional 25,000 square feet of new space for immediate use and another 30,000 square feet that the company plans to occupy over the next six months. The space, which totals 105,000 square feet, will be used for quality assurance, quality control and R&D and other functions.
“Securing more space was a priority in honoring our anthrax contract with the US government,” said Lance Gordon, president and CEO of VaxGen. “As we continue to rapidly grow and plan for the future as a biologics company focused on infectious diseases, it is important for us to have state-of-the-art facilities.”
rpa102 is a recombinant vaccine candidate based on technology developed by the US Army Medical Research Institute of Infectious Diseases (USAMRIID). It has been under development by USAMRIID for more than a decade, under an initiative to create a safe anthrax vaccine requiring no more than three injections.